


SARS-CoV-2 Neutralizing Antibody **ELISA** Kit



Introduction

SARS-CoV-2 Neutralizing Antibody ELISA Kit is used for in vitro qualitative/semi-quantitative detection of whether there are neutralizing antibodies against SARS-CoV-2 RBD in the serum, plasma, and whole blood of vaccine vaccinators and recovered patients to assess the body's immune status. This product is suitable for testing by medical institutions at all levels, providing an important supplementary synergy for nucleic acid testing, and better serving the prevention and control of the epidemic.

Features

Good specificity and high accuracy

High sensitivity, as high as 97%; Good repeatability


Easy to operate, 2 hours to complete the detection; High throughput

Widely used to help epidemic prevention and control

Theory

Infection with the SARS-CoV-2 initiates an immune response, which includes the production of antibodies in the blood. The protein-protein interaction between RBD and ACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD, which provide protection against future infections from viruses (Figure a).

Recombinant human ACE2 receptor protein is used to coat the ELISA microtiter plate, and horseradish peroxidase (HRP) is used to label the new coronavirus (SARS-CoV-2) RBD protein to prepare the enzyme conjugate RBD-HRP to achieve qualitative detection of the level of neutralizing antibodies in the test sample (Figure b).




Schematic diagram of neutralizing antibody blocking virus invasion (a)
ELISA to detect neutralizing antibodies (b)

Application



Neutralizing antibody screening



RUO



Vaccine potency assessment



Epidemiological screening

GUANGDONG ARDENT BIOMED Co., Ltd.

Tel: 020-82207223 400-8783-223

Web: <http://www.ardentbiomed.com.cn/>

Add: The 4th floor, C1 building, No.11 Kaiyuan avenue, Guangzhou City, Guangdong Province, China.



Scan and follow